23.03.2015 • News

Oschmann Set to Become Merck KGaA's CEO

Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to replace current CEO Karl-Ludwig Kley next year, Manager Magazin reported on Friday.

Oschmann, 57, would take on the new role next year after the group's annual shareholder meeting in April 2016 or in September next year at the latest, when Kley's current contract expires.

The German drugs and chemicals maker last September appointed Oschmann, the head of its pharma business at the time, as deputy chief executive from January 2015 on, sharing strategic management functions and representation of the company with Kley (63).

A Merck spokeswoman said a decision on Kley's succession has not yet been made and that this would be a matter for the family-controlled group's board of partners.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read